Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCB-003
- Development stage
- Preclinical
- Lead developer
- Castle Creek Biosciences
- Modality
- Gene Therapies
- Administration
- Intradermal
01
Overview
CCB-003 is a disease-modifying gene therapy under development for the treatment of Ehlers-Danlos syndrome, specifically targeting the delivery of a functional type III collagen gene (COL3A1). The therapy aims to address underlying genetic defects by transferring the COL3A1 gene, which encodes collagen type III alpha 1 chain, to restore normal collagen function. Originally developed by Mayo Clinic and now being advanced by Castle Creek Biosciences, CCB-003 is currently in preclinical development. Its primary indication is for congenital disorders affecting skin and musculoskeletal systems, with a focus on Ehlers-Danlos syndrome[1][2].
Beyond the preview
Go deeper on CCB-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCB-003.